Aerobic capacity and disease activity in children, adolescents and young adults with juvenile idiopathic arthritis (JIA)
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1546-0096
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Aerobic capacity and disease activity in children, adolescents and young adults with juvenile idiopathic arthritis (JIA) ; volume:10 ; number:1 ; day:20 ; month:8 ; year:2012 ; pages:1-8 ; date:12.2012
Pediatric rheumatology ; 10, Heft 1 (20.8.2012), 1-8, 12.2012
- Creator
-
van Pelt, Philomine A.
Takken, Tim
van Brussel, Marco
de Witte, Mirjam
Kruize, Aike A.
Wulffraat, Nico M.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/1546-0096-10-25
- URN
-
urn:nbn:de:101:1-2021082819002388590302
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:26 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- van Pelt, Philomine A.
- Takken, Tim
- van Brussel, Marco
- de Witte, Mirjam
- Kruize, Aike A.
- Wulffraat, Nico M.
- SpringerLink (Online service)
Other Objects (12)
Aerobic capacity and disease activity in children, adolescents and young adults with juvenile idiopathic arthritis (JIA)
Adalimumab treatment in Juvenile Idiopathic Arthritis (JIA) patients with special focus on Uveitis
How do parents of children with juvenile idiopathic arthritis (JIA) perceive their therapies?
Testing population-based performance measures identifies gaps in juvenile idiopathic arthritis (JIA) care
The successes and challenges of harmonising juvenile idiopathic arthritis (JIA) datasets to create a large-scale JIA data resource
4.4 Different phenotype of anaemia in systemic juvenile idiopathic arthritis (s-JIA) compared to anaemia in other subtypes of JIA
PReS-FINAL-2159: Tocilizumab (TCZ) dosing in juvenile idiopathic arthritis (JIA): optimising for different JIA type and body weight patients
Application of the Yamaguchi criteria for classification of “suspected” systemic juvenile idiopathic arthritis (sJIA)
A meta-analysis to estimate the “real” placebo effect in juvenile idiopathic arthritis (JIA) trials
Medication therapy patients with juvenile idiopathic arthritis (JIA), who needed joint replacement in adult life
Methotrexate for the treatment of juvenile idiopathic arthritis: process to approval for JIA indication in Japan
Quality improvement in juvenile idiopathic arthritis: a mixed-methods implementation pilot of the CAPTURE-JIA dataset
Aerobic capacity and disease activity in children, adolescents and young adults with juvenile idiopathic arthritis (JIA)
Adalimumab treatment in Juvenile Idiopathic Arthritis (JIA) patients with special focus on Uveitis
How do parents of children with juvenile idiopathic arthritis (JIA) perceive their therapies?
Testing population-based performance measures identifies gaps in juvenile idiopathic arthritis (JIA) care
The successes and challenges of harmonising juvenile idiopathic arthritis (JIA) datasets to create a large-scale JIA data resource
4.4 Different phenotype of anaemia in systemic juvenile idiopathic arthritis (s-JIA) compared to anaemia in other subtypes of JIA
PReS-FINAL-2159: Tocilizumab (TCZ) dosing in juvenile idiopathic arthritis (JIA): optimising for different JIA type and body weight patients
Application of the Yamaguchi criteria for classification of “suspected” systemic juvenile idiopathic arthritis (sJIA)
A meta-analysis to estimate the “real” placebo effect in juvenile idiopathic arthritis (JIA) trials
Medication therapy patients with juvenile idiopathic arthritis (JIA), who needed joint replacement in adult life
Methotrexate for the treatment of juvenile idiopathic arthritis: process to approval for JIA indication in Japan
Quality improvement in juvenile idiopathic arthritis: a mixed-methods implementation pilot of the CAPTURE-JIA dataset
Aerobic capacity and disease activity in children, adolescents and young adults with juvenile idiopathic arthritis (JIA)
Adalimumab treatment in Juvenile Idiopathic Arthritis (JIA) patients with special focus on Uveitis
How do parents of children with juvenile idiopathic arthritis (JIA) perceive their therapies?
Testing population-based performance measures identifies gaps in juvenile idiopathic arthritis (JIA) care
The successes and challenges of harmonising juvenile idiopathic arthritis (JIA) datasets to create a large-scale JIA data resource
4.4 Different phenotype of anaemia in systemic juvenile idiopathic arthritis (s-JIA) compared to anaemia in other subtypes of JIA
PReS-FINAL-2159: Tocilizumab (TCZ) dosing in juvenile idiopathic arthritis (JIA): optimising for different JIA type and body weight patients
Application of the Yamaguchi criteria for classification of “suspected” systemic juvenile idiopathic arthritis (sJIA)
A meta-analysis to estimate the “real” placebo effect in juvenile idiopathic arthritis (JIA) trials
Medication therapy patients with juvenile idiopathic arthritis (JIA), who needed joint replacement in adult life
Methotrexate for the treatment of juvenile idiopathic arthritis: process to approval for JIA indication in Japan